143 related articles for article (PubMed ID: 38251564)
1. Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study.
Unizony S; Matza MA; Jarvie A; O'Dea D; Fernandes AD; Stone JH
Lancet Rheumatol; 2023 Dec; 5(12):e736-e742. PubMed ID: 38251564
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab for giant cell arteritis.
Antonio AA; Santos RN; Abariga SA
Cochrane Database Syst Rev; 2022 May; 5(5):CD013484. PubMed ID: 35560150
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
Villiger PM; Adler S; Kuchen S; Wermelinger F; Dan D; Fiege V; Bütikofer L; Seitz M; Reichenbach S
Lancet; 2016 May; 387(10031):1921-7. PubMed ID: 26952547
[TBL] [Abstract][Full Text] [Related]
4. Trial of Tocilizumab in Giant-Cell Arteritis.
Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schett G; Schulze-Koops H; Spiera R; Unizony SH; Collinson N
N Engl J Med; 2017 Jul; 377(4):317-328. PubMed ID: 28745999
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab for giant cell arteritis.
Antonio AA; Santos RN; Abariga SA
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD013484. PubMed ID: 34420204
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study.
Christ L; Seitz L; Scholz G; Sarbu AC; Amsler J; Bütikofer L; Tappeiner C; Kollert F; Reichenbach S; Villiger PM
Lancet Rheumatol; 2021 Sep; 3(9):e619-e626. PubMed ID: 38287611
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.
Venhoff N; Schmidt WA; Bergner R; Rech J; Unger L; Tony HP; Finzel S; Andreica I; Kofler DM; Weiner SM; Lamprecht P; Schulze-Koops H; App C; Pournara E; Mendelson MH; Sieder C; Maricos M; Thiel J
Lancet Rheumatol; 2023 Jun; 5(6):e341-e350. PubMed ID: 38251601
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.
Stone JH; Han J; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Spiera R; Unizony SH; Bao M;
Lancet Rheumatol; 2021 May; 3(5):e328-e336. PubMed ID: 38279390
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study.
Samson M; Devilliers H; Ly KH; Maurier F; Bienvenu B; Terrier B; Charles P; Guillevin L; Besancenot JF; Liozon E; Fauchais AL; Loffroy R; Binquet C; Audia S; Seror R; Mariette X; Bonnotte B
Eur J Intern Med; 2018 Nov; 57():96-104. PubMed ID: 30054122
[TBL] [Abstract][Full Text] [Related]
10. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
Stone JH; Spotswood H; Unizony SH; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Spiera R; Bao M
Rheumatology (Oxford); 2022 Jul; 61(7):2915-2922. PubMed ID: 34718434
[TBL] [Abstract][Full Text] [Related]
11. Ustekinumab for the Treatment of Giant Cell Arteritis.
Matza MA; Fernandes AD; Stone JH; Unizony SH
Arthritis Care Res (Hoboken); 2021 Jun; 73(6):893-897. PubMed ID: 32248659
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
[TBL] [Abstract][Full Text] [Related]
13. Treatment failure in giant cell arteritis.
Unizony SH; Bao M; Han J; Luder Y; Pavlov A; Stone JH
Ann Rheum Dis; 2021 Nov; 80(11):1467-1474. PubMed ID: 34049857
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
Cid MC; Unizony SH; Blockmans D; Brouwer E; Dagna L; Dasgupta B; Hellmich B; Molloy E; Salvarani C; Trapnell BC; Warrington KJ; Wicks I; Samant M; Zhou T; Pupim L; Paolini JF;
Ann Rheum Dis; 2022 May; 81(5):653-661. PubMed ID: 35264321
[TBL] [Abstract][Full Text] [Related]
15. Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis.
Adler S; Reichenbach S; Gloor A; Yerly D; Cullmann JL; Villiger PM
Rheumatology (Oxford); 2019 Sep; 58(9):1639-1643. PubMed ID: 30915462
[TBL] [Abstract][Full Text] [Related]
16. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
Devauchelle-Pensec V; Carvajal-Alegria G; Dernis E; Richez C; Truchetet ME; Wendling D; Toussirot E; Perdriger A; Gottenberg JE; Felten R; Fautrel BJ; Chiche L; Hilliquin P; Le Henaff C; Dervieux B; Direz G; Chary-Valckenaere I; Cornec D; Guellec D; Marhadour T; Nowak E; Saraux A
JAMA; 2022 Sep; 328(11):1053-1062. PubMed ID: 36125471
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and tolerance of tocilizumab for corticosteroid sparing in giant cell arteritis and aortitis: Experience of Nimes University Hospital about eleven patients].
Broner J; Arnaud E
Rev Med Interne; 2018 Feb; 39(2):78-83. PubMed ID: 29221884
[TBL] [Abstract][Full Text] [Related]
18. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Burmester GR; Buttgereit F; Bernasconi C; Álvaro-Gracia JM; Castro N; Dougados M; Gabay C; van Laar JM; Nebesky JM; Pethoe-Schramm A; Salvarani C; Donath MY; John MR;
Lancet; 2020 Jul; 396(10246):267-276. PubMed ID: 32711802
[TBL] [Abstract][Full Text] [Related]
19. The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study.
Kreis L; Dejaco C; Schmidt WA; Németh R; Venhoff N; Schäfer VS
Trials; 2024 Jan; 25(1):56. PubMed ID: 38225579
[TBL] [Abstract][Full Text] [Related]
20. The Cost-Effectiveness of Tocilizumab (Actemra) Therapy in Giant Cell Arteritis.
Jogimahanti AV; Kini AT; Irwin LE; Lee AG
J Neuroophthalmol; 2021 Sep; 41(3):342-350. PubMed ID: 34415267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
